Combination of Baricitinib and Remdesivir May Shorten COVID-19 Recovery Time

Study Overview

Recent research indicates that adding the arthritis medication baricitinib to the antiviral drug remdesivir may decrease recovery time for adults hospitalized with COVID-19. This study highlights the ongoing efforts by scientists and healthcare professionals to identify effective treatments for patients affected by SARS-CoV-2.

Background on Treatments

Previously, remdesivir was found to be effective in treating COVID-19 patients. Researchers have noted that a dysregulated inflammatory response significantly contributes to the severe symptoms associated with the virus. Consequently, they hypothesized that an anti-inflammatory treatment like baricitinib could enhance recovery outcomes when used in conjunction with remdesivir.

Study Details and Findings

The findings from this study were published in the New England Journal of Medicine, involving 1,033 patients diagnosed with COVID-19 and pneumonia across eight countries. Participants received remdesivir for up to ten days and were randomly assigned to receive either baricitinib for up to fourteen days or a placebo. Specifically, 515 patients were administered baricitinib, while 518 received the placebo.

Statistical analyses were performed to evaluate the impact of these treatments on recovery time. Results showed that patients receiving the combination treatment had a median recovery time of seven days, compared to eight days for those treated with remdesivir alone.

The most significant benefits were observed in patients requiring high-flow oxygen or non-invasive ventilation, whose recovery time improved dramatically from eighteen days to ten days due to the combination therapy. Additionally, participants experienced improved clinical conditions and a reduction in adverse effects.

Future Research Directions

Further research is essential to better understand the role of baricitinib in the management of COVID-19. Future studies should focus on comparing baricitinib with standard care practices and identifying which specific patient populations may gain the most benefit from this treatment.

Reference

Kalil AC., Patterson TF., Mehta AK., Tomashek KM., Wolfe CR., Ghazaryan V., et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020 Dec 11. doi: 10.1056/NEJMoa2031994.